Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. The company has built a cystic fibrosis (CF) empire, bringing in billions of dollars in revenue annually, and now is ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

In its first quarter 2025 investor letter, GreensKeeper Asset Management emphasized stocks such as Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by RBC Capital, and Vertex Pharmaceuticals maintained their sector perform rating. The last upgrade for Vertex ...